Envista (NYSE:NVST) Stock Rating Upgraded by Mizuho

Envista (NYSE:NVST) was upgraded by equities research analysts at Mizuho from a “strong sell” rating to a “hold” rating in a note issued to investors on Tuesday, Marketbeat.com reports. The firm presently has a $24.00 price target on the stock, up from their previous price target of $19.00. Mizuho’s price objective would indicate a potential downside of 2.79% from the company’s current price.

Several other research analysts also recently weighed in on NVST. Robert W. Baird set a $27.00 price target on Envista in a report on Friday, October 31st. Barclays started coverage on Envista in a research note on Monday, December 8th. They issued an “overweight” rating and a $24.00 target price for the company. Stifel Nicolaus set a $25.00 price target on Envista in a research note on Thursday, October 30th. Evercore ISI reaffirmed an “outperform” rating on shares of Envista in a research note on Friday, October 31st. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Envista in a report on Monday, December 29th. Five analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $22.15.

Envista Price Performance

NYSE:NVST opened at $24.69 on Tuesday. Envista has a 12-month low of $14.22 and a 12-month high of $25.41. The firm has a market cap of $4.06 billion, a price-to-earnings ratio of 274.34, a price-to-earnings-growth ratio of 1.09 and a beta of 0.99. The company’s 50-day moving average is $21.77 and its two-hundred day moving average is $20.88. The company has a current ratio of 2.37, a quick ratio of 2.02 and a debt-to-equity ratio of 0.47.

Envista (NYSE:NVST) last posted its quarterly earnings data on Wednesday, October 29th. The company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The business had revenue of $669.90 million during the quarter, compared to analyst estimates of $639.49 million. Envista had a net margin of 0.58% and a return on equity of 5.90%. The company’s revenue was up 11.5% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.12 earnings per share. Research analysts expect that Envista will post 1 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ariel Investments LLC grew its stake in Envista by 1.7% during the second quarter. Ariel Investments LLC now owns 12,355,666 shares of the company’s stock worth $241,430,000 after buying an additional 210,921 shares during the period. Dimensional Fund Advisors LP boosted its position in Envista by 4.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 9,537,874 shares of the company’s stock worth $194,284,000 after purchasing an additional 367,363 shares during the period. Franklin Resources Inc. increased its holdings in Envista by 16.7% in the 2nd quarter. Franklin Resources Inc. now owns 8,956,572 shares of the company’s stock valued at $175,011,000 after purchasing an additional 1,284,767 shares in the last quarter. Alliancebernstein L.P. raised its position in Envista by 34.0% in the second quarter. Alliancebernstein L.P. now owns 6,098,445 shares of the company’s stock valued at $119,164,000 after purchasing an additional 1,547,656 shares during the period. Finally, Clarkston Capital Partners LLC lifted its stake in shares of Envista by 0.4% during the second quarter. Clarkston Capital Partners LLC now owns 4,703,330 shares of the company’s stock worth $91,903,000 after purchasing an additional 16,583 shares in the last quarter.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.